Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | muscleblind-like splicing regulator 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | muscleblind protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Echinococcus multilocularis | muscleblind protein 1 | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Brugia malayi | Muscleblind-like protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Echinococcus granulosus | muscleblind protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Loa Loa (eye worm) | hypothetical protein | Get druggable targets OG5_132352 | All targets in OG5_132352 |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | aspartyl aminopeptidase | 0.0077 | 0.2835 | 0.2127 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Echinococcus granulosus | muscleblind protein | 0.018 | 1 | 1 |
Trypanosoma cruzi | aspartyl aminopeptidase, putative | 0.0077 | 0.2835 | 0.5 |
Echinococcus multilocularis | aspartyl aminopeptidase | 0.0077 | 0.2835 | 0.2127 |
Entamoeba histolytica | aminopeptidase, putative | 0.0077 | 0.2835 | 0.5 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0077 | 0.2835 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0077 | 0.2835 | 0.2127 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0077 | 0.2835 | 1 |
Mycobacterium tuberculosis | Probable aminopeptidase PepC | 0.0077 | 0.2835 | 0.5 |
Leishmania major | aspartyl aminopeptidase, putative,metallo-peptidase, Clan MH, Family M20 | 0.0077 | 0.2835 | 0.5 |
Trichomonas vaginalis | Clan MH, family M18, aspartyl aminopeptidase-like metallopeptidase | 0.0077 | 0.2835 | 1 |
Schistosoma mansoni | aspartyl aminopeptidase (M18 family) | 0.0077 | 0.2835 | 1 |
Echinococcus multilocularis | muscleblind protein | 0.018 | 1 | 1 |
Trypanosoma brucei | aspartyl aminopeptidase, putative | 0.0077 | 0.2835 | 0.5 |
Trypanosoma cruzi | metallo-peptidase, Clan MH, Family M20 | 0.0077 | 0.2835 | 0.5 |
Echinococcus granulosus | aspartyl aminopeptidase | 0.0077 | 0.2835 | 0.2127 |
Entamoeba histolytica | aspartyl aminopeptidase, putative | 0.0077 | 0.2835 | 0.5 |
Trypanosoma brucei | aspartyl aminopeptidase, putative | 0.0077 | 0.2835 | 0.5 |
Plasmodium vivax | M18 aspartyl aminopeptidase, putative | 0.0077 | 0.2835 | 0.5 |
Echinococcus multilocularis | muscleblind protein 1 | 0.018 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0077 | 0.2835 | 0.2127 |
Plasmodium falciparum | M18 aspartyl aminopeptidase | 0.0077 | 0.2835 | 0.5 |
Mycobacterium leprae | PROBABLE AMINOPEPTIDASE PEPC | 0.0077 | 0.2835 | 0.5 |
Brugia malayi | Aspartyl aminopeptidase | 0.0077 | 0.2835 | 0.2127 |
Schistosoma mansoni | aspartyl aminopeptidase (M18 family) | 0.0077 | 0.2835 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | 7.0795 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 112.2018 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540273] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.